Kuros Biosciences Ltd. (CH:KURN)

:KURN

KURN

Kuros Biosciences

RESEARCH TOOLSreports

Want to see CH:KURN full AI Analyst Report?

Kuros Biosciences (KURN) Price & Analysis

8 Followers

KURN Stock Chart & Stats

CHF28.16

-CHF0.35(-1.68%)

At close: Mar 06 4:00 PM EST

CHF28.16

-CHF0.35(-1.68%)

Day’s Range― - ―

52-Week RangeCHF19.60 - CHF34.20

Previous CloseN/A

Volume98.33K

Average Volume (3M)128.87K

Market Cap

CHF796.05M

Enterprise ValueCHF812.59M

Total Cash (Recent Filing)CHF15.66M

Total Debt (Recent Filing)CHF3.94M

Price to Earnings (P/E)498.6

Beta1.49

Next Earnings

Aug 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.09

Shares Outstanding39,253,124

10 Day Avg. Volume110,510

30 Day Avg. Volume128,868

Financial Highlights & Ratios

PEG Ratio-3.21

Price to Book (P/B)15.78

Price to Sales (P/S)8.71

P/FCF Ratio-439.50

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF38.00

Price Target Upside34.94% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)0.35

Revenue Forecast (FY)CHF200.65M

Bulls Say, Bears Say

Bulls Say

Revenue Scaling / Market AdoptionSustained multi-year revenue scaling indicates durable market adoption of MagnetOs and related bone graft products across surgical channels. A per‑unit sales model with distributor and hospital penetration supports repeatable revenue growth and long-term upside as procedures and formulary access expand.

Very High Gross MarginsPersistent ~86% gross margins reflect product-level pricing power and low variable cost intensity, creating a structural profitability advantage versus commodity graft substitutes. High gross margin supports reinvestment in sales/clinical work and improves leverage as revenue scales, sustaining long-term operating profitability.

Conservative Balance Sheet / Low LeverageVery low leverage and a growing asset base give the company financial flexibility to fund commercialization and R&D without immediate solvency pressure. A conservative capital structure reduces bankruptcy risk and supports tactical investments or targeted acquisitions over the next several quarters.

Bears Say

Weak Cash ConversionCash generation lagged reported profits in 2025 as operating cash turned slightly negative and free cash flow fell meaningfully from 2024. If working‑capital or capex drains persist, the business faces higher funding needs and constrained ability to self‑fund commercial expansion over coming quarters.

Thin Net Profitability CushionAlthough the company reached positive operating and net income in 2025, margins remain thin. A small profit buffer leaves results vulnerable to reimbursement pressure, surgical volume fluctuations, or pricing concessions, increasing downside risk to sustainable earnings.

Near‑term Funding SensitivityNegative free cash flow and weakened operating cash in 2025 raise the odds the company may need external financing to sustain growth or inventory build. Dependence on capital markets or partners could affect strategic timing and increase execution risk over the next several quarters.

Kuros Biosciences News

Kuros Biosciences posts 51% Q1 sales surge on MagnetOs growth and manufacturing expansion

Kuros Biosciences ( ($CH:KURN) ) has issued an announcement. Kuros Biosciences reported a 51% year-on-year increase in total...

19d ago

Kuros Biosciences Hits Record Sales and First Profit as MagnetOs Fuels Global Expansion

Kuros Biosciences ( ($CH:KURN) ) just unveiled an update. Kuros Biosciences reported a 72% jump in 2025 medical...

2M ago

Kuros Biosciences’ MagnetOs Study: A Potential Game-Changer in Spinal Fusion

Kuros Biosciences (($CSBTF)) announced an update on their ongoing clinical study. Study Overview: Kuros Biosciences is conducting a...

6M ago

CSBTF

Kuros Biosciences’ Clinical Study on MagnetOs Flex Matrix: A Potential Game-Changer in Spinal Fusion

Kuros Biosciences (($CSBTF)) announced an update on their ongoing clinical study. Kuros Biosciences is conducting a phase IV...

6M ago

CSBTF

Kuros Biosciences Reports Strong Revenue Growth and Strategic Expansion

The latest announcement is out from Kuros Biosciences ( ($CH:KURN) ). Kuros Biosciences announced a 77% year-over-year increase...

7M ago

Kuros Biosciences Investigates Allegations Against Former Board Member

Kuros Biosciences ( ($CH:KURN) ) has shared an update. Kuros Biosciences is addressing media inquiries regarding the resignation...

8M ago

Kuros Biosciences Announces Board of Directors Changes

Kuros Biosciences ( ($CH:KURN) ) has provided an announcement. Kuros Biosciences announced changes to its Board of Directors,...

8M ago

Kuros Biosciences Reports Strong Revenue Growth in 2025

Kuros Biosciences ( ($CSBTF) ) has released its Q2 earnings. Here is a breakdown of the information Kuros...

9M ago

Kuros Biosciences Achieves Record Growth and First Operating Profit in H1 2025

Kuros Biosciences ( ($CH:KURN) ) has shared an update. Kuros Biosciences reported a 78% increase in total medical...

9M ago

Kuros Biosciences Achieves 82% Sales Growth in Q1 2025

The latest announcement is out from Kuros Biosciences ( ($CH:KURN) ). Kuros Biosciences reported an 82% year-over-year increase...

1y ago

KURN FAQ

What was Kuros Biosciences Ltd.’s price range in the past 12 months?

Kuros Biosciences Ltd. lowest stock price was CHF19.60 and its highest was CHF34.20 in the past 12 months.

What is Kuros Biosciences Ltd.’s market cap?

Kuros Biosciences Ltd.’s market cap is CHF796.05M.

When is Kuros Biosciences Ltd.’s upcoming earnings report date?

Kuros Biosciences Ltd.’s upcoming earnings report date is Aug 12, 2026 which is in 102 days.

How were Kuros Biosciences Ltd.’s earnings last quarter?

Kuros Biosciences Ltd. released its earnings results on Mar 10, 2026. The company reported CHF0.093 earnings per share for the quarter, beating the consensus estimate of CHF0 by CHF0.093.

Is Kuros Biosciences Ltd. overvalued?

According to Wall Street analysts Kuros Biosciences Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kuros Biosciences Ltd. pay dividends?

Kuros Biosciences Ltd. does not currently pay dividends.

What is Kuros Biosciences Ltd.’s EPS estimate?

Kuros Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kuros Biosciences Ltd. have?

Kuros Biosciences Ltd. has 39,253,124 shares outstanding.

What happened to Kuros Biosciences Ltd.’s price movement after its last earnings report?

Kuros Biosciences Ltd. reported an EPS of CHF0.093 in its last earnings report, beating expectations of CHF0. Following the earnings report the stock price went up 10.609%.

Which hedge fund is a major shareholder of Kuros Biosciences Ltd.?

Currently, no hedge funds are holding shares in CH:KURN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Kuros Biosciences Ltd.

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.

Kuros Biosciences (KURN) Earnings & Revenues

Historic Earnings Reports

KURN Company Deck

KURN Earnings Call

Q4 2026

0:00 / 0:00

KURN Stock 12 Month Forecast

Average Price Target

CHF38.00

▲(34.94% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"CHF19","24":"CHF24","29":"CHF29","34":"CHF34","39":"CHF39"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,24,29,34,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.28,21.643076923076926,23.006153846153847,24.36923076923077,25.732307692307693,27.095384615384617,28.458461538461542,29.821538461538463,31.184615384615384,32.54769230769231,33.91076923076923,35.27384615384615,36.63692307692308,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.28,21.643076923076926,23.006153846153847,24.36923076923077,25.732307692307693,27.095384615384617,28.458461538461542,29.821538461538463,31.184615384615384,32.54769230769231,33.91076923076923,35.27384615384615,36.63692307692308,{"y":38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.28,21.643076923076926,23.006153846153847,24.36923076923077,25.732307692307693,27.095384615384617,28.458461538461542,29.821538461538463,31.184615384615384,32.54769230769231,33.91076923076923,35.27384615384615,36.63692307692308,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.72,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":25.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.86,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.12,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.48,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.78,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.08,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.28,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >